

In re: Shirley *et al.*

Appl. No.: 09/187,661

Express Mailed: November 6, 1998

Page 2

A1  
concluded in a concentration of at least about 250 mg/ml, wherein said variant is a polypeptide that has IGF-I activity and differs from the amino acid sequence for said human IGF-I by up to 10 amino acid residues.

Please cancel claim 2 without prejudice or disclaimer.

Please amend claim 3, as follows:

A2  
2. (amended) The [IGF-I] composition of claim [2]1, wherein said [syrup comprises] human IGF-I or variant thereof is present in a concentration of about 250 mg/ml to about 500 mg/ml.

Please amend claim 4, as follows:

A3  
3. (amended) The [IGF-I] composition of claim [2]1, wherein said [syrup comprises] human IGF-I or variant thereof is present in a concentration of about 350 mg/ml, and wherein said [syrup] composition has a density of about 1.07 g/ml and a viscosity of about 15,700 cps.

Please cancel claims 8 and 12 without prejudice or disclaimer.

Please amend claim 13, as follows:

A4  
4  
13. (amended) A kit for reconstituting a pharmaceutical composition comprising biologically active human IGF-I or biologically active variant thereof, said kit comprising [a carrier being compartmentalized to receive in close confinement therein one or more container means, wherein one of said container means contains a highly concentrated form of biologically active IGF-I or variant thereof, wherein said IGF-I or variant thereof is present in a concentration of at least about 250 mg/ml,] the composition of claim 1 and [another of said container means contains] a pharmaceutically acceptable buffered solution having a pH less than or equal to about pH 5.0.

Please amend claim 16, as follows:

A5  
15  
16. (amended) A [composition prepared according to the method of claim 15, wherein said composition is a] pharmaceutical composition comprising the composition of claim 1.

A6  
8  
17. (amended) A [composition prepared according to the method of claim 15, wherein said composition is a ]cryogenically produced PLGA microsphere comprising the composition of claim 1.

9  
8  
20. (amended) The microsphere of claim 18, wherein said microsphere comprises a lyophilized form of said [syrup]composition.

Please add the following new claims:

A7  
10  
--28. The composition of claim 1, wherein said variant differs from the amino acid sequence for said human IGF-I by up to 5 amino acid residues.

11  
29. The composition of claim 1, wherein said variant differs from the amino acid sequence for said human IGF-I by up to 2 amino acid residues.

12  
30. The composition of claim 1, wherein said variant differs from the amino acid sequence for said human IGF-I by 1 amino acid residue.

13  
31. The composition of claim 1, wherein said human IGF-I is recombinant human IGF-I.

14  
13  
32. The composition of claim 31, wherein said recombinant human IGF-I is present at a concentration of about 250 mg/ml to about 500 mg/ml.

15  
~~38.~~

13

The composition of claim ~~34~~, wherein said recombinant human IGF-I is present in a concentration of about 350 mg/ml, and wherein said composition has a density of about 1.07 g/ml and a viscosity of about 15,700 cps.

16  
~~34.~~

A low salt-containing composition comprising biologically active human IGF-I in a concentration of at least about 250 mg/ml.

17  
~~38.~~

16

The composition of claim ~~34~~, wherein said human IGF-I is recombinant human IGF-I.

18  
~~38.~~

16

The composition of claim ~~34~~, wherein said human IGF-I is present in a concentration of about 250 mg/ml to about 500 mg/ml.

19  
~~37.~~

16

The composition of claim ~~34~~, wherein said human IGF-I is present in a concentration of about 350 mg/ml, and wherein said composition has a density of about 1.07 g/ml and a viscosity of about 15,700 cps.

20  
~~38.~~

16

A pharmaceutical composition comprising the composition of claim ~~34~~.

21  
~~38.~~

A cryogenically produced PLGA microsphere comprising the composition of claim ~~34~~.

22  
~~40.~~

19

A pharmaceutical composition comprising the composition of claim ~~37~~.

23  
~~41.~~

A cryogenically produced PLGA microsphere comprising the composition of claim ~~37~~.

30

A